In addition to significant improvements in 5-year OS and PFS with maintenance rituximab, there was a trend toward an association between maintenance and reduced transformation risk.
The statement emphasizes strategies for multidisciplinary care, and proposes an algorithm for clinical management of bone metastasis in RCC.
PFS, tumor response, and safety outcomes were similar in patient cohorts under age 75 vs those 75 years of age and older.
A team from Children’s Healthcare of Atlanta reports unexpected factors determining which adolescents participated in sperm banking.
Three and 6 months after undergoing the psychotherapeutic intervention Managing Cancer and Living Meaningfully (CALM), participants reported less-severe depressive symptoms.
A small study has found that men with cancer were less likely than women to prefer palliative care if informed that continued treatment would not be helpful.
While over half of survivors had heard of metabolic syndrome, in one-third with the condition, fewer than 10% had been diagnosed; educational strategies may be of benefit.
The OS benefit associated with standard treatment diminished in patients older than 80 with high comorbidity scores, but other age groups fared better.
There may be prophylactic benefit from using lenalidomide, an orally bioavailable CNS-penetrating agent, combined with R-CHOP in the upfront setting.
Investigators concluded ixazomib “may offer a more convenient, active, and well-tolerated alternative to a parenterally administered PI in this setting.”